Literature DB >> 20194150

Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic.

Ingemar Turesson1, Ramon Velez, Sigurdur Y Kristinsson, Ola Landgren.   

Abstract

OBJECTIVE: To define age-adjusted incidence trends in multiple myeloma (MM) in a well-characterized population during a long period, given that some, but not all, studies have reported increasing MM incidence over time and that clinical experience from some centers suggests an increased incidence mainly in younger age groups. PATIENTS AND METHODS: We identified all patients (N=773) with MM diagnosed in Malmö, Sweden, from January 1, 1950, through December 31, 2005. Using census data for the population of Malmö, we calculated age- and sex-specific incidence rates. Incidence rates were also calculated for 10-year birth cohorts. Analyses for trends were performed using the Poisson regression.
RESULTS: From 1950 through 2005, the average annual age-adjusted (European standard population) incidence rate remained stable (Poisson regression, P=.07 for men and P=.67 for women). Also, comparisons between 10-year birth cohorts (from 1870-1879 to 1970-1979) failed to detect any increase. Between 1950-1959 and 2000-2005, the median age at diagnosis of MM increased from 70 to 74 years, and the proportion of newly diagnosed patients aged 80 years or older increased from 16% to 31%.
CONCLUSION: Our finding of stable MM incidence rates for all age groups during the past 5 decades suggests that recent clinical observations of an increase of MM in the young may reflect an increased referral stream of younger patients with MM, which in turn might be a consequence of improved access to better MM therapies. Importantly, because of the aging population, the proportion of patients with MM aged 80 years or older doubled between 1950-1959 and 2000-2005.

Entities:  

Mesh:

Year:  2010        PMID: 20194150      PMCID: PMC2843108          DOI: 10.4065/mcp.2009.0426

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  25 in total

1.  A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK.

Authors:  K J Phekoo; S A Schey; M A Richards; D H Bevan; S Bell; D Gillett; H Møller
Journal:  Br J Haematol       Date:  2004-11       Impact factor: 6.998

Review 2.  Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis.

Authors:  O Landgren; B M Weiss
Journal:  Leukemia       Date:  2009-07-09       Impact factor: 11.528

3.  Trends in the incidence of multiple myeloma in Denmark 1943-1982: a study of 5500 patients.

Authors:  N E Hansen; H Karle; J H Olsen
Journal:  Eur J Haematol       Date:  1989-01       Impact factor: 2.997

4.  Cancer statistics, 2000.

Authors:  R T Greenlee; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  2000 Jan-Feb       Impact factor: 508.702

5.  Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978.

Authors:  B Mattsson; A Wallgren
Journal:  Acta Radiol Oncol       Date:  1984

6.  Cancer incidence and mortality trends in the United States: 1935-74.

Authors:  S S Devesa; D T Silverman
Journal:  J Natl Cancer Inst       Date:  1978-03       Impact factor: 13.506

7.  Increasing trends of multiple myeloma mortality in England and Wales; 1950-79: are the changes real?

Authors:  R Velez; V Beral; J Cuzick
Journal:  J Natl Cancer Inst       Date:  1982-08       Impact factor: 13.506

Review 8.  Cancer incidence and mortality trends among whites in the United States, 1947-84.

Authors:  S S Devesa; D T Silverman; J L Young; E S Pollack; C C Brown; J W Horm; C L Percy; M H Myers; F W McKay; J F Fraumeni
Journal:  J Natl Cancer Inst       Date:  1987-10       Impact factor: 13.506

9.  Comparison of trends in the incidence of multiple myeloma in Malmö, Sweden, and other countries, 1950-1979.

Authors:  I Turesson; O Zettervall; J Cuzick; J G Waldenstrom; R Velez
Journal:  N Engl J Med       Date:  1984-02-16       Impact factor: 91.245

10.  Multiple myeloma in the United States, 1950--1975.

Authors:  W A Blattner; A Blair; T J Mason
Journal:  Cancer       Date:  1981-12-01       Impact factor: 6.860

View more
  30 in total

Review 1.  Second malignancies after multiple myeloma: from 1960s to 2010s.

Authors:  Anish Thomas; Sham Mailankody; Neha Korde; Sigurdur Y Kristinsson; Ingemar Turesson; Ola Landgren
Journal:  Blood       Date:  2012-02-06       Impact factor: 22.113

2.  Baseline platelet count and creatinine clearance rate predict the outcome of neutropenia-related invasive aspergillosis.

Authors:  Simone Aranha Nouér; Marcio Nucci; Naveen Sanath Kumar; Monica Grazziutti; Alejandro Restrepo; Elias Anaissie
Journal:  Clin Infect Dis       Date:  2012-03-15       Impact factor: 9.079

3.  Treat or palliate: outcomes of very elderly myeloma patients.

Authors:  Fotios Panitsas; Jaimal Kothari; Grant Vallance; Faouzi Djebbari; Lisa Ferguson; Manuela Sultanova; Karthik Ramasamy
Journal:  Haematologica       Date:  2017-10-12       Impact factor: 9.941

4.  Dexamethasone-induced oxidative stress enhances myeloma cell radiosensitization while sparing normal bone marrow hematopoiesis.

Authors:  Soumen Bera; Suzanne Greiner; Amit Choudhury; Angela Dispenzieri; Douglas R Spitz; Stephen J Russell; Apollina Goel
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

Review 5.  Efficacy and safety of busulfan-based conditioning regimens for multiple myeloma.

Authors:  Donna Reece; Kevin Song; Richard LeBlanc; Khalid Mezzi; Ade Olujohungbe; Darrell White; Faraz Zaman; Andrew Belch
Journal:  Oncologist       Date:  2013-04-29

Review 6.  Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival.

Authors:  Ingemar Turesson; Magnus Bjorkholm; Cecilie Hveding Blimark; Sigurdur Kristinsson; Ramon Velez; Ola Landgren
Journal:  Eur J Haematol       Date:  2018-04-20       Impact factor: 2.997

7.  Patient, Physician and Contextual Factors Are Influential in the Treatment Decision Making of Older Adults Newly Diagnosed with Symptomatic Myeloma.

Authors:  Joseph D Tariman; Ardith Doorenbos; Karen G Schepp; Pamela S Becker; Donna L Berry
Journal:  Cancer Treat Commun       Date:  2014

8.  Management of Elderly Patients with Plasma Cell Myeloma.

Authors:  Erica L Campagnaro; Teresa E Goebel; Hillard M Lazarus
Journal:  Drugs Aging       Date:  2015-06       Impact factor: 3.923

Review 9.  Aging: Treating the Older Patient.

Authors:  Ashley Rosko; Andrew Artz
Journal:  Biol Blood Marrow Transplant       Date:  2016-11-15       Impact factor: 5.742

10.  Latent cytomegalovirus infection enhances anti-tumour cytotoxicity through accumulation of NKG2C+ NK cells in healthy humans.

Authors:  A B Bigley; K Rezvani; N Shah; T Sekine; N Balneger; M Pistillo; N Agha; H Kunz; D P O'Connor; C M Bollard; R J Simpson
Journal:  Clin Exp Immunol       Date:  2016-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.